Impact of liberalizing eligibility criteria. (A) Stage from stage III to IV disease to stage II to IV disease and (B) platelet requirement from platelets ≥150 000 to platelets ≥75 000 on EFS in the MER cohort. Blue lines represent patients included by the stringent specifications of stage and platelet requirements. Yellow lines represent patients additionally included by liberalizing stage and platelet requirements. P values are obtained from log-rank tests comparing the 2 survival curves shown in each plot.